Department of Medicine, Lombardi Comprehensive Cancer Center.
Department of Oral Diagnostic Sciences, State University of New York at Buffalo.
J Immunother. 2019 Nov/Dec;42(9):345-347. doi: 10.1097/CJI.0000000000000288.
Immunotherapy has advanced the treatment of solid organ malignancies. Although generally well tolerated, treatment with immune checkpoint inhibitors can be complicated by immune-related adverse events, some of which are relatively uncommon. We report the first case of gingival linear immunoglobulin A disease related to treatment with an antiprogrammed cell death protein 1 antibody. A 73-year-old male with advanced non-small cell lung cancer achieved a durable response to nivolumab monotherapy. After 1 year of treatment, he developed gingival swelling and pain. Biopsy revealed linear immunoglobulin A disease of the gingiva which was effectively treated with systemic steroids. Ongoing vigilance for immune-mediated toxicity is paramount during and after treatment with immune checkpoint inhibitors.
免疫疗法已经推进了实体器官恶性肿瘤的治疗。虽然通常具有良好的耐受性，但免疫检查点抑制剂的治疗可能会出现免疫相关的不良反应，其中一些相对少见。我们报告了首例与抗程序性死亡蛋白 1 抗体治疗相关的牙龈线性免疫球蛋白 A 病。一名 73 岁的男性患有晚期非小细胞肺癌，对纳武利尤单抗单药治疗有持久反应。治疗 1 年后，他出现牙龈肿胀和疼痛。活检显示为牙龈线性免疫球蛋白 A 病，全身皮质类固醇治疗有效。在接受免疫检查点抑制剂治疗期间和治疗后，对免疫介导的毒性进行持续监测至关重要。
